Agios Pharmaceuticals Inc (NASDAQ:AGIO) was the target of some unusual options trading activity on Thursday. Stock traders acquired 3,119 call options on the company. This represents an increase of approximately 1,790% compared to the average volume of 165 call options.
Agios Pharmaceuticals (NASDAQ:AGIO) opened at $75.11 on Friday. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $76.02. The stock has a market cap of $3,660.00, a price-to-earnings ratio of -11.98 and a beta of 1.83.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the business posted ($1.63) EPS. Agios Pharmaceuticals’s revenue was up 26.4% compared to the same quarter last year. equities research analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current year.
In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00. Following the transaction, the insider now owns 56,059 shares in the company, valued at approximately $3,643,835. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $63.85, for a total transaction of $383,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 32,130 shares of company stock worth $2,039,260 in the last 90 days. 5.43% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. FMR LLC grew its position in Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after purchasing an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after purchasing an additional 617,379 shares during the last quarter. BlackRock Inc. grew its position in Agios Pharmaceuticals by 23.5% in the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after purchasing an additional 508,306 shares during the last quarter. Alkeon Capital Management LLC acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth $30,489,000. Finally, Janus Henderson Group PLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth $20,423,000. Institutional investors own 93.79% of the company’s stock.
AGIO has been the topic of a number of recent research reports. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $75.00.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.